Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Date:10/26/2009

2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Zerenex (ferric citrate), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for Zerenex; our ability to meet anticipated development timelines for Zerenex due to recruitment, clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our planned Phase 3 clinical program the efficacy and safety of Zerenex observed in the previous Phase 2 and the Open Label Extension clinical trials, and the effects on IV iron and EPO use observed in these previous clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that oc
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
2. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Drug Safety Strategies and Risk ... clinical success ...
... FRANCISCO, Calif., Oct. 26, 2011 Onyx Pharmaceuticals, ... results from a Bayer HealthCare Pharmaceuticals Phase 3 ... for the treatment of patients with metastatic colorectal ... standard therapies. The trial met its primary endpoint ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 2Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 3Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 4Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 5
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... Hills, California (PRWEB) December 25, 2014 ... her home in Woodland Hills, California after an 8 ... passed away on Christmas Eve evening in her home ... with aggressive metastatic breast cancer. , ... for over forty years, she pioneered and championed many ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , , , , ... of the 32 filed cases around the country have filed a joint ... to Chief Judge James G. Carr of the United States District Court ... July 24, 2009, before the Judicial Panel on Multidistrict Litigation in Washington, ...
... MONICA, Calif., July 24 The following advisory was issued by Consumer Watchdog: , , ... health insurance , , When : , ... , Hilton , Civil Justice Foundation Breakfast of Champions , ... San Francisco, CA 94102 , , What : , ...
... , , WASHINGTON, July 24 ... Department of Veterans Affairs (VA) medical centers, attained over one billion ... , , "Using this technology, ... database, allowing VA physicians immediate access to patient records regardless of ...
... The Hispanic got milk? Milk Mustache,Mobile Tour visited New York as ... to reintroduce Hispanics to this nutrient powerhouse and its,array of benefits. ... local residents not only to live well, but to drink well,with ... the events, Hispanic mothers were given the opportunity to enter the,Milk ...
... Medicine finds suggestive but limited evidence that exposure to Agent ... associated with an increased chance of developing ischemic heart disease ... the latest in a congressionally mandated series by the IOM ... effects of these herbicides and a type of dioxin -- ...
... , , OKLAHOMA CITY, July ... continues to see job opportunities for qualified professionals in the Oklahoma City, ... 6%, Adecco USA currently has demand for 100 pharmacy technicians in the ... , , Over the past year the ...
Cached Medicine News:Health News:Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio 2Health News:CIGNA Whistleblower Calls for More Heath Insurance Accountability in Heath Care Reform 2Health News:VA Medical Imaging Reaches Record Level 2Health News:The Hispanic got milk? Campaign Visited New York July 18 - July 22 2Health News:Limited data suggest possible association between Agent Orange exposure 2Health News:Limited data suggest possible association between Agent Orange exposure 3Health News:Wanted: Oklahoma City Licensed Pharmacy Technicians 2
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Latex Agglutination Slide Test for the Qualitative and Semi-Quantitative Determination of D-Dimer in plasma, 60 tests....
Medicine Products: